Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells

Cancer Biology and Therapy

Volumn 4, Issue 8, 2005, Pages 866-871

  Zupi, Gabriella ^a   Scarsella, Marco ^a   D'Angelo, Carmen ^a   Biroccio, Annamaria ^a   Paoletti, Giancarlo ^a   Lopez, Massimo ^a   Leonetti, Carlo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Breast cancer; Cell cycle; Chemotherapy; Combination; Mice; Tumor cells

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FARMARUBICINA; GEMCITABINE; PACLITAXEL; ANTHRACYCLINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GRAFT; CANCER INHIBITION; CELL COMPARTMENTALIZATION; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; SEQUENTIAL ANALYSIS; XENOGRAFT; BREAST TUMOR; COMPARATIVE STUDY; DRUG SCREENING;

ANTHRACYCLINES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MICE; PACLITAXEL; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 25144481893     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.8.1895     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Winer EP, Morrow M, Osborne CK. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg RA, eds. Cancer: Principles & Practice of Oncology. Sixth Edition. Philadelphia: Lippincott Williams & Wilkins, 2001:1651-17.
3. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P, TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968-75.
4. Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Moulopoulos LA, Economopoulos T, Pectasides D, Maniadakis N, Siafaka V, Briasoulis E, Christodoulou C, Tsavdaridis D, Makrantonakis P, Razis E, Kosmidis P, Skarlos D, Dimopoulos MA. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004; 15:1517-26.
5. Seidman AD. The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1995; 1:247-56.
6. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003; 9:124-33.
7. Poplin EA, Corbett T, Flaherty L, Tarasoff P, Redman BG, Valdivieso M, Baker L. Difluorodeoxycytidine (dFdC) - gemcitabine: A phase 1 study. Invest New Drugs 1992; 10:165-70.
8. Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003; 64:191-206.
9. Brandi M, Vici P, Lopez M, Valerio MR, Giotta F, Gebbia N, Schittulli F, Colucci G. Gruppo oncologico italia meridionale. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: Results of a multicenter phase II study. Semin Oncol 2004; 31:13-9.
10. Colomer R, Llombart-Cussac A, Lluch A, Barnadas A, Ojeda B, Caranana V, Fernandez Y, Garcia-Conde J, Alonso S, Montero S, Hornedo J, Guillem V. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 2004; 15:201-6.
11. Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska A, Pawlicki M, Melemed AS, O'Shaughnessy J, Reyes JM. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Proc Am Soc Clin Oncol 2004; 23:5, (Abstr 510).
12. Perez-Manga G, Lluch A, Alba E, Moreno-Nogueira JA, Palomero M, Garcia-Conde J, Khayat D, Rivelles N. Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a phase II pharmacokinetic trial. J Clin Oncol 2000; 18:2545-52.
13. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade III JL, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003; 21:3249-54.
14. Smorenburg CH, Sparrenboom A, Bontenbal M, Verweij J. Combination chemotherapy of the taxanes and antimetabolites: Its use and limitations. Eur J Cancer 2001; 37:2310-23.
15. Kroep JR, Giaccone G, Tolis C, Voorn DA, Loves WJ, Groeningen CJ, Pinedo HM, Peters GJ. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in nonsmall-cell lung cancer cell lines. Br J Cancer 2000; 83:1069-76.
16. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ. Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with nonsmall-cell lung cancer. J Clin Oncol 1999; 17:2190-7.
17. Geran RI, Greenberg NH, Macdonald MM, Shumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Ed. 3. Cancer Chemother Rep 1972; 3:1-88.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
19. Silvestris N, D'Aprile M, Andreola G, Locopo N, Marini L, Crucitta E, De Lena M, Lorusso V. Rationale for the use of gemcitabine in breast cancer. Int J Oncol 2004; 24:389-98.
20. Robinson BW, Im MM, Ljungman M, Praz F, Shewach DS. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res 2003; 63:6935-41.
21. Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a nonfunctional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002; 97:439-45.
22. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332:1004-14.
23. Cividalli A, Mauro F, Livdi E, Ceciarelli F, Altavista P, Cruciani G, Tirindelli Danesi D. Schedule dependent toxicity and efficacy of combined gemcitabine/paclitaxel treatment in mouse adenocarcinoma. J Cancer Res Clin Oncol 2000; 126:461-67.